Abstract
Abstract. Naringin is a citrus-flavonoid which has been shown to have positive metabolic and anti-inflammatory effects. For this reason, we believe it would be interesting to study the effects of Naringin administration on body weight, BMI, lipid profile and adiponectin levels in patients with dyslipidemia, especially considering that dyslipidemias along with obesity and subsequent cardiometabolic complications are some of the most important public health issues plaguing our society today. A double-blind, randomized clinical trial was conducted in a group of 28 adult patients previously diagnosed with dyslipidemia who attended the Institute of Experimental and Clinical Therapeutics. Patients were divided into two groups; the first group (n = 14) received 450 mg of naringin every 24 hours, in the mornings, while the second group (n = 14) was given a homologated placebo over the course of a 90-day period. Significant differences were observed in naringin group compared to the placebo group in terms of decreased BMI (30.6 ± 3.19 vs 33.3 ± 3.23 kg/m2; p = 0.03), total cholesterol (182 ± 20.2 vs 245 ± 24.1 mg/dl; p < 0.01), LDL cholesterol (100 ± 17.5 vs 125 ± 38.3 mg/dl; p = 0.03) and an increase in adiponectin levels (0.82 ± 0.25 vs 0.59 ± 0.19 μg/ml; p = 0.01). Our results support the use of Naringin as a potential therapeutic agent which could play an important role in the management of metabolic disorders.
References
1 WHO, editor. Global action plan for the prevention and control of noncommunicable diseases 2013–2020. 2013. Available from: https://apps.who.int/iris/bitstream/handle/10665/94384/9789241506236_eng.pdf;jsessionid=45D0850A33B38B94DE1767A1FCB27BC2?sequence=1
2 Encuesta Nacional de Salud y Nutrición 2012. Resultados Nacionales
[National Survey of Health and Nutrition 2012. National Results] . Cuernavaca, Mexico: Instituto Nacional de Salud Pública (MX); 2012. Available from: https://ensanut.insp.mx/informes/ENSANUT2012ResultadosNacionales.pdf3 Methodological design of the half-way National Health and Nutrition Survey 2016. Salud Publica Mex. 2017;59:299–305.
4 . Prevalence of dyslipidemias in Mexico City and its association with other cardiovascular risk factors. Results of the Study CARMELA. Gac Med Mex. 2014;150:128–36.
5 . Emerging role of adipocytokines in type 2 diabetes as mediators of insulin resistance and cardiovascular disease. Can J Diabetes. 2018;42(4):446–56.e1.
6 . Polyphenols and microvascular function in humans: A systematic review. Curr Pharm Des. 2018;24(2):203–26.
7 . Phenolic acids in foods: An overview of analytical methodology. J. Agric Food Chem. 2003;51(10):2866–87.
8 . Effects of flavonoids on vascular smooth muscle of the isolated rat thoracic aorta. Life Sci. 2003;74(5):603–12.
9 Novel insights of dietary polyphenols and obesity. J Nutr Biochem. 2014;25(1):1–18.
10 . Use of herbal products and potential interactions in patients with cardiovascular diseases. JACC. 2010;55(6):515–25.
11 . Preventive effect of naringin on metabolic syndrome and its mechanism of action: A systematic review. Evid Based Complement Alternat Med [Internet]. 2019 Feb;3(2019):9752826.
12 . Preclinical evidence for the pharmacological actions of naringin: A review. Planta Med. 2014;80(06):437–51.
13 . Transcriptional regulation of human and rat hepatic lipid metabolism by the grapefruit flavonoid naringenin: Role of PPARalpha, PPARgamma and LXRalpha. PLoS One. 2010;5(8):e12399. https://doi.org/10.1371/journal.pone.0012399
14 Naringin supplementation lowers plasma lipids and enhances erythrocyte antioxidant enzyme activities in hypercholesterolemic subjects. Clin Nutr. 2003;22(6):561–8.
15 . Effect of citrus flavonoids, naringin and naringenin, on metabolic syndrome and their mechanisms of action. Adv Nutr. 2014;5(4):404–17.
16 . Pharmacokinetic, pharmacodynamic and formulations aspects of naringenin: An update. Life Sci. 2018;215:43–56.
17 . Therapeutic potential of naringin: An overview. Pharm Biol. 2016;54(12):3203–10.
18 .
Analysis of data . In: Chin RLee BY, editors. Principles and practice of clinical trial medicine. London: Academic Press; 2008. p. 325–59.19 . Nutraceuticals inspiring the current therapy for lifestyle diseases. Adv Pharmacol Sci. 2019;2019:6908716. https://doi.org/10.1155/2019/6908716
20 Nutraceuticals as an important part of combination therapy in dyslipidaemia. Curr Pharm Des. 2017;23(17):2496–503.
21 Lipid-modifying effects of nutraceuticals: An evidence-based approach. Nutrition. 2016;32(11–12):1179–92.
22 Lipid lowering nutraceuticals in clinical practice: Position paper from an International Lipid Expert Panel. Arch Med Sci. 2017;13(5):965–1005.
23 Optimizing cholesterol treatment in patients with muscle complaints. J Am Coll Cardiol. 2017;70(10):1290–301.
24 Naringin time-dependently lowers hepatic cholesterol biosynthesis and plasma cholesterol in rats fed high-fat and high-cholesterol diet. J Med Food. 2006;9(4):582–6.
25 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):3234–37. https://doi.org/10.1016/j.jacc.2018.11.002
26 . Guidelines for the treatment of dyslipidemias in adults: Adult Treatment Panel III (ATP-III). Endocrinol Nutr. 2004;51(5):254–65.
27 . Comparison of the lipid-lowering effects of pitavastatin 4 mg versus pravastatin 40 mg in adults with primary hyperlipidemia or mixed (combined) dyslipidemia: A Phase IV, prospective, US, multicenter, randomized, double-blind, superiority trial. Clin Ther. 2014;36(8):1211–22.
28 . Effectiveness of statins. What and when should we measure? Acta Med Colomb. 2016;41(3):163–6.
29 A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis. 2002;162(2):373–9. Erratum in: Atherosclerosis. 2003;168(2):401.
30 . Thambiah SC. Effects of different types of statins on lipid profile: A perspective on Asians. Int J Endocrinol Metab. 2017;15(2):E43319. https://doi.org/10.5812/ijem.43319
31 Fatty acids consumption: The role metabolic aspects involved in obesity and its associated disorders. Nutrients. 2017;9(10):1158. https://doi.org/10.3390/nu9101158
32 . Naringin alters the cholesterol biosynthesis and antioxidant enzyme activities in LDL receptor-knockout mice under cholesterol fed condition. Life Sci. 2004;74(13):1621–34.
